FDA approves PTC’s ultra-rare disease gene therapy for broader patient population than Europe
The FDA has cleared PTC Therapeutics’ gene therapy for AADC deficiency, an ultra-rare disease that impacts the nerve cells and brain.
The gene therapy was …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
